Article Text

Download PDFPDF
The significance of substance P in physiological and malignant haematopoiesis
  1. Michal Nowicki1,
  2. Danuta Ostalska-Nowicka2,
  3. Beata Kondraciuk1,
  4. Bogdan Miskowiak3
  1. 1Department of Histology and Embryology, Poznan University of Medical Sciences, Poland
  2. 2Department of Pediatric Cardiology and Nephrology, Poznan University of Medical Sciences, Poland
  3. 3Department of Optometry and Biology of the Visual System, Poznan University of Medical Sciences, Poland
  1. Correspondence to:
 Dr Michal Nowicki
 Department of Histology and Embryology, Poznan University of Medical Sciences, ul. Swiecickiego 6, 60-781 Poznan, Poland; mnowicki{at}


The role of substance P (SP) in physiological haematopoiesis is well established. However, it also seems to be important in the neoplastic transformation of bone marrow, leading to the development of acute leukaemia in children, and also metastases to bone marrow of solid tumours (particularly neuroblastoma and breast cancer) in early stages of these diseases. This review summarises the available data on SP involvement in both processes. In the future, SP antagonists may be used as anti-neoplastic drugs, for example by direct or indirect blocking of tumour cell proliferation through inhibition of growth factor production and interleukin-1b synthesis.

  • ALL, acute lymphocytic leukaemia
  • BM, bone marrow
  • G-CSF, granulocyte colony stimulating factor
  • GM-CSF, granulocyte monocyte colony stimulating factor
  • HK, haemokinin
  • HSC, haematopoietic stem cell
  • IL, interleukin
  • MSC, mesenchymal stem cell
  • NK, neurokinin
  • NK-R, neurokinin receptor
  • PPT, preprotachykinin
  • SCF, stem cell factor
  • SP, substance P
  • substance P
  • tachykinins
  • hematopoiesis
  • malignancy

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Published Online First 15 December 2006

  • Competing interests: None.